Fresenius Medical Care AG & Co. KGaA (FMS) Expected to Announce Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings of $0.59 per share and revenue of $5.4062 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Saturday, February 14th. The company reported $1.69 earnings per share for the quarter. The firm had revenue of $5.95 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.0%

NYSE:FMS opened at $22.50 on Monday. The firm has a market capitalization of $12.57 billion, a P/E ratio of 11.78, a PEG ratio of 2.74 and a beta of 0.81. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46. The company’s fifty day moving average price is $22.86 and its 200-day moving average price is $23.56. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, March 13th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, January 27th. Erste Group Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Six investment analysts have rated the stock with a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $28.00.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares in the last quarter. Arax Advisory Partners increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth about $58,000. Finally, Group One Trading LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the third quarter worth about $74,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.